Comment on: Empirical antibiotic monotherapy for febrile neutropenia: Systematic review and meta-analysis of randomized controlled trials [1]

Journal of Antimicrobial Chemotherapy

Volumn 58, Issue 2, 2006, Pages 478-

  Rolston, Kenneth V I ^a   Bodey, Gerald P ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Ceftazidime; Febrile neutropenia; Monotherapy

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CEFEPIME; CEFTAZIDIME; CEPHALOSPORIN; EXTENDED SPECTRUM BETA LACTAMASE; PIPERACILLIN PLUS TAZOBACTAM; POLYPEPTIDE ANTIBIOTIC AGENT; VANCOMYCIN;

ANALYTICAL ERROR; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL INFECTION; CLINICAL TRIAL; ENTEROBACTER; ENTEROBACTERIACEAE; EPIDEMIOLOGICAL DATA; EVIDENCE BASED MEDICINE; FEBRILE NEUTROPENIA; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; IN VITRO STUDY; KLEBSIELLA; LETTER; MEDICAL DECISION MAKING; MEDICAL SOCIETY; META ANALYSIS; MONOTHERAPY; PATIENT CARE; PRACTICE GUIDELINE; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; FEVER; HUMANS; META-ANALYSIS; META-ANALYSIS AS TOPIC; NEUTROPENIA; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 33748047129     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl193     Document Type: Letter

References (10)

1. Paul M, Yahav D, Fraser A et al. Empirical antibiotic monotherapy for febrile neutropenia: Systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 2006; 57: 176-89.
2. Hughes WT, Pizzo PA, Wade JC et al. Evaluation of new anti-infective drugs for the treatment of febrile episodes in neutropenic patients. Clin Infect Dis 1992; 15 Suppl 1: 206-15.
3. Wisplinghoff H, Seifert H, Wenzel RP et al. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis 2003; 36: 1103-10.
4. Winston DJ, Lazarus HM, Beveridge RA et al. Randomized, double-blind, multicenter trial comparing clinafloxacin with imipenem as empirical monotherapy for febrile granulocytopenic patients. Clin Infect Dis 2001; 32: 381-90.
5. Del Favero A, Menichetti F, Martino P et al. A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia. Clin Infect Dis 2001; 33: 1295-301.
6. Yadegarynia D, Tarrand J, Raad I et al. Current spectrum of bacterial infections in cancer patients. Clin Infect Dis 2003; 37: 1144-5.
7. Jones RN, Biedenbach DJ, Gales AC. Sustained activity and spectrum of selected extended-spectrum β-lactams (carbapenems and cefepime) against Enterobacter spp. and ESBL-producing Klebsiella spp.: Report from the SENTRY antimicrobial surveillance program (USA, 1997-2000). Int J Antimicrob Agents 2003; 21: 1-7.
8. Masterton RG, Turner PJ. Trends in antimicrobial susceptibility in UK centres: The MYSTIC Programme (1997-2002). Int J Antimicrob Agents 2006; 27: 69-72.
9. Glasmacher A, von Lilienfeld-Toal M, Schulte S et al. An evidence-based evaluation of important aspects of empirical antibiotic therapy in febrile neutropenic patients. Clin Microbiol Infect 2005; 11 Suppl 5: 17-23.
10. Rolston KVI. Challenges in the treatment of infections caused by gram-positive and gram-negative bacteria in patients with cancer and neutropenia. Clin Infect Dis 2005; 40: S246-52.